YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Prevalence of Strains Resistant to the Third Generation Cephalosporins among Clinical Isolates and Identification of TEM Type $\beta$-lactamase from Resistant Strains by PCR Method

3 세대 세파계 항생제에 내성인 임상균주의 분포와 PCR 법을 이용한 TEM type $\beta$-lactamase 생산균주의 동정

  • 김무용 (LG 화학 기술연구원, 바이오텍연구소) ;
  • 오정인 (LG 화학 기술연구원, 바이오텍연구소) ;
  • 송혜경 (LG 화학 기술연구원, 바이오텍연구소) ;
  • 백경숙 (LG 화학 기술연구원, 바이오텍연구소) ;
  • 곽진환 (LG 화학 기술연구원, 바이오텍연구소)
  • Published : 1995.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

Compared to the first and second-generation cephalosporins, the third-generation cephalosporins are remarkably stable against hydrolysis by the $\beta$-lactamases produced by aerobic gram-negative bacilli, such as Enterobacteriaceae. Among these bacteria, the most prevalent plasmid-encoded $\beta$-lactamase is TEM-1 $\beta$-lactamase belonging to class A or group 2b. This enzyme is produced constitutively and is principally active against peniciflins and old cephalosporins rather than third-generafion cephalosporins, carbapenems and mmobactams. However, new TEM type $\beta$-lactamases including TEM-9 and TEM-12 evolved through point mutations in a gene encoding $\beta$-lactamase have been discovered from patients during chemotherapy. These $\beta$-lactamases are known to be capable of hydrolyzing most of the third-generatim cephalosporins. To study the prevalence of $\beta$-lactamases from clinical isolates collected in Korea. the minimal inhibitory concentratims(MICs) of several third-generation cephalosporins against 628 clinical isolates were determined by agar dilution methods, and $\beta$-lactamas-producing bacteria were isolated by use of cefinase disc. By polymerase chain reaction (PCR) method, clinical isolates harboring a gene for TEM type $\beta$-lactamase were identified among the $\beta$-lactamase producing strains. Twentiy three percent of the clinical isolates was resistant to the thirdgeneration cephalosporins, and more than 90% of resistant cells produced various $\beta$-lactamases. TFM type $\beta$-lactamases were dominant in gram-negative bacilli, such as Escherichia coli, Klebsiella pneumoniae, Enterobacter species. These results suggest the necessity of the development of new cephalosporins which are stable against $\beta$-lactamases like TEM.

Keywords

References

  1. J. Clin. Pharmacol. v.30 Third generation cephalosporins, Safety profiles after 10 years of clinical use Neu,H.C.
  2. Science v.264 Inactivation of antibiotics and the dissemination of resistance gene Davies,J.
  3. Antimicrob. Agents and Chemother v.27 Role of β-lactam hydrolysis in the mechanism of resistance of a β-lactamase constitutive Enterobacter cloacae strains to extended spectrum β-lactams Vu,H.;Nikaido,H.
  4. Pharmacol. Ther. v.27 Role of permeability barriers in resis-tance to β-lactam antibiotics Nikaido,H.
  5. Antimicrob. Agents and Chemother v.27 Resistance caused by decreased penetration of β-lactam antibiotics into Enterobacter cloacae Bush,K.;Tanaka,S.K.;Bonner,D.P.;Sykes,R.B.
  6. J. Antimicrob. Chemothr. v.33 Bacterial resistance mechanisms as thera-peutic targets Coleman,K.;Athalye,M.;Davison,M.;Payne,D.J.;Perry,C.R.;Chopra,I.
  7. Science v.264 Prevention of drug access to bacterial targets: Permeability barriers and active efflux Nikaido,H.
  8. Science v.264 Resistance to antibiotics mediated by target alterations Spratt,B.G.
  9. Clin. Infec. Dis. v.15 β-Lactam resistance in gram negative bacteria: global trends and clinical impact Sanders,C.C.;W.E.Sanders,Jr.
  10. Antimicrob. Agents Chemother v.35 More extended-spectrum β-lactamase Jacoby,G.A.;Medeiros,A.A.
  11. J. Antimicrb. Chemothr. v.33 Convergent evolution of TEM-26, a β-lactamase with extended-spectrum activity Hibbert-Rogers,L.C.F.;Heritage,J.;Hawkey,P.M.
  12. Antimicrob. Agents. Chemother. v.39 New extended TEM-type β-lactamase from Salmonella enterica subsp, enterica isolated in nosocomial outbreak Morosini,M.I.;Canton,R.;Negri,M.C.;Baquero,F.;Blazquez,J.
  13. Antimicrob. Agents Chemother v.32 Sequence of PSE-2 β-lactamase Huovien,P.;Hurovinen,S.;Jacoby,G.A.
  14. Antimicrob. Agents Chemother v.38 Lerner Reversal of clavulanate resistance conferred by Ser-244 mutant of TEM-1 β-lactamase as a result of second mutation Imtiaz,U.;Manavathu,E.K.;Lerner,S.A.
  15. Philos. Trans. R. Soc. London B v.289 The genetic basis of the spread of β-lactamase synthesis among plasmid carrying bacteria Richmond,M.H.
  16. Antimicrob. Agents Chemother v.35 Properties of plasmids responsible for extended-spectrum β-lactamase production Jacoby,G.A.
  17. Document M7-A2: Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically National Committee for Clinical Laboratory Standards(NCCLS)
  18. J. Clin. Microbiol. v.9 Chromogenic cephalosporin spot test to detect beta β-lactamase in clinically significant bacteria Montagomery,K.;Raymundo,Jr.
  19. Nucl. Acids. Res. v.17 Direct clone characterization from plaque and colonies by the polymerase chain reaction Gussow,D.;Clackson,T.
  20. Antimicrob. Agents Chemother v.33 Characterization of β-lactamase Bush,K.
  21. Antimicrob. Agents Chemother v.36 Nucleotide Sequences of CAZ-2, CAZ-6, and CAZ-7 β-lactamase gene Chanal,C.;Poupart,M.C.;Sirot,D.;Labia,R.;Sirot,J.;Cluzel,R.
  22. J. Antibiotics v.48 Synthesis and biological activity of novel cephalosporins containing a(Z)-vinyl dimethylphosphonate group Smith,P.W.;Chamiec,A.J.;Chung,G.;Cobley,K.N.;Wood,M.R.
  23. J. Antimicrb. Chemother. In vitro and in vivo antibacterial activities of LB10517, a novel catechol-substituted cephalosporin with broad antibacterial spectrum Song,H.K.;Oh,J.I.;Kim,M.Y.;Kim,Y.Z.;Kim,I.C.;Kwak,J.H.